Oasis Outsourcing Ranked in 2014 Top Private Companies by Florida Trend

West Palm Beach, FL Jun 27, 2014 – Oasis Outsourcing ranked eighth in the Florida Trend Florida’s Biggest Private Companies list for 2014. The rankings of the 225 privately held companies, with headquarters in Florida, are based on the previous year’s revenue. Oasis, one of the nation’s largest Professional Employer Organizations (PEOs), ranked eighth in 2013 as well. For more information, click here.
“We are pleased to once again be ranked in the top 10 largest private companies in Florida, compiled by Florida Trend,” said Mark Perlberg, President and CEO of Oasis Outsourcing. “It’s an honor to be included among the many other successful Florida businesses. We continue to be proud of our growth, not only in Florida, but nationwide.”

Precyse Thought Leadership on Display at HFMA ANI 2014

Performance Management Company also offers the only HFMA Peer Reviewed HIM Technology and Services Suite
Wayne, PA and Alpharetta, GA Jun 23, 2014 — Precyse, a leader in health information management (HIM) technology and services, is driving health information performance at the Healthcare Financial Management Association’s Annual National Institute (HFMA ANI), June 22-26 at the Sands Expo Center in Las Vegas, Booth #736.
On Wednesday, June 26, Teresa Michael, RHIT, Director of Health Information Management, Sarasota Memorial Health Care System and Mark Hendricks, RHIA, Commercial General Manager and Vice President, Precyse will present, “Advancing Clinical Documentation Quality and Accuracy While Preparing for ICD-10.” This presentation will outline how Sarasota Memorial Health Care System made a substantial impact on their bottom line by implementing a comprehensive clinical documentation improvement (CDI) program. Hendricks’ and Michael’s presentation will take place 7:00-7:50 a.m.
In Precyse booth #736, industry experts will be available to discuss the only HFMA Peer Reviewed HIM Technology and Services Suite. The Precyse portfolio includes precyseCode and precyseCDI, the only single, integrated platform enabling both inpatient and outpatient computer assisted coding and clinical documentation improvement (CDI). The Cloud-based platform incorporates state-of-art Natural Language Processing (NLP) for embedded intelligence and supports multiple HIM roles within an organization. In a KLAS report titled “Computer-Assisted Coding: A Glimpse at the Future of HIM Technology,” Precyse was “praised for [its] strong technology and…received the highest scores of providers” perception that their solution will meet their needs.”i
KLAS has also recognized Precyse University, the most innovative and complete on-site, online and mobile healthcare education solution that is revolutionizing the way that 1.6 million healthcare professionals learn, in the recent KLAS report, “ICD-10 Consulting Services: Who Can Help in the Eleventh Hour.”ii
“Precyse continues to drive performance management by delivering products and services that optimize financial opportunity by positively impacting clinical documentation and quality,” said Chris Powell, CEO, Precyse. “Appropriate clinical documentation leads to appropriate reimbursement for care. Our combination of technology and services helps organizations drive internal performance and maximize value.”
The Precyse HFMA Peer Reviewed HIM Technology and Services Suite includes HIM sourcing, interim management and consulting, coding, CDI, auditing, cancer registry, Best in KLAS Transcription, plus ICD-10 education.

AMRI to Acquire Oso Biopharmaceuticals Manufacturing

Significantly Expands Contract Manufacturing Capabilities to Include Commercial Scale Sterile Injectables
Albany, NY Jun 2, 2014 – AMRI (NASDAQ: AMRI) today announced that it has signed a definitive agreement to acquire all of the outstanding membership interests of Oso Biopharmaceuticals Manufacturing, LLC (“OsoBio”) for $110 million in cash. OsoBio is recognized as a premier contract manufacturer of highly complex injectable drug products, including sterile liquid, suspension and lyophilized formulations. The acquisition and associated fees are expected to be financed through cash currently held by AMRI, and, subject to Hart-Scott-Rodino clearance and other conditions to closing, is expected to be completed in the third quarter of 2014.
“The acquisition of OsoBio is highly complementary to our finished dose manufacturing business, and is consistent with our strategy to be the preeminent supplier of custom and complex drug development services and products to the pharmaceutical industry,” said William S. Marth, AMRI’s president and chief executive officer. “OsoBio adds significantly to our sterile manufacturing capabilities, extending our industry-leading position in early stage contract manufacturing to now include OsoBio’s preeminent large-scale commercial production. In addition, we expect to realize savings in capital costs associated with the previously planned facility expansion.”
“We are very excited about the synergies that our Albuquerque operations will bring to AMRI as part of their organization,” said Milton Boyer, OsoBio’s President. “The addition of AMRI’s experience and capabilities in early phase development greatly increases the value proposition for our customers, providing a single source to address all sterile fill/finish needs from phase 1 development complete to commercial supply.”
Located in Albuquerque, New Mexico, OsoBio is a trusted, long-time partner to many of the industry’s leading pharmaceutical companies and is well respected for its expertise in manufacturing complex injectables, its reliability of supply and superior track record of quality. OsoBio’s core capabilities include liquid fill and lyophilized products, highly potent compounds, cytotoxics, proteins and peptides, monoclonal antibodies, vaccines, liposomal suspensions and controlled substances. OsoBio has provided manufacturing support for more than 250 unique products and their attractive development pipeline, which includes multiple late-stage products, is expected to be important contributor for future growth.
On a stand-alone basis, OsoBio’s forecasted full year 2014 revenue is between $58 million and $60 million, with adjusted EBITDA of between $9 million and $10 million, implying a purchase price multiple of 11 times 2014 adjusted EBITDA at the top end of the range. Adjusted EBITDA excludes any deal related costs or purchase accounting impacts.
AMRI anticipates full year run-rate synergies of approximately $3 million of EBITDA within 12 months of closing. Subject to Hart-Scott-Rodino clearance, the Company anticipates the acquisition will be accretive to 2014 earnings and intends to provide investors with updated 2014 guidance for the combined company when it releases its second quarter 2014 financial results. OsoBio is expected to continue to operate independently within AMRI’s Drug Product business unit. Milton Boyer, the current president and chief executive officer, will lead the OsoBio team and report into Steven Hagen, Ph.D., AMRI’s senior vice president of manufacturing and pharmaceuticals.